-
Feb 19, 2021 12:32 PM IST The approved product is a generic version of Lundbeck NA Ltd's Northera capsules.
-
Feb 19, 2021 10:44 AM IST Valuation at a discount to peers, but significant scope for margin improvement
-
Feb 16, 2021 05:24 PM IST Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated February 11, 2021.
-
Feb 15, 2021 06:59 PM IST ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1165 in its research report dated February 11, 2021.
-
Feb 12, 2021 11:06 AM IST In the injectables space, Aurobindo Pharma remains constructive and targets to almost double from current annual sales base of $380 million to $650-700 million in three years backed by new plants in the US and Vizag
-
Feb 11, 2021 10:44 AM IST -
Feb 11, 2021 10:44 AM IST -
Feb 10, 2021 10:20 PM IST The company had posted a net profit of Rs 705.31 crore in the corresponding period of the previous fiscal, Aurobindo Pharma said in a filing to BSE.
-
Jan 18, 2021 10:47 PM IST Net Sales are expected to increase by 15.5 percent Y-o-Y (up 5 percent Q-o-Q) to Rs. 5,799.4 crore, according to Prabhudas Lilladher.
-
Dec 18, 2020 01:46 PM IST Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1024 in its research report dated December 17, 2020.
-
Dec 11, 2020 08:32 AM IST Vaccine rollout will throw up opportunities not just for the domestic pharmaceutical and healthcare industry but also the logistics value chain, right from vaccine production, delivery, storage and then the actual immunisation
-
Dec 01, 2020 12:13 PM IST Earlier, Aurobindo Pharma Managing Director N Govindarajan had said that proceeds from Natrol’s divestiture will be used to reduce debt and other new strategic initiatives.
-
Nov 18, 2020 01:57 PM IST Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 921 in its research report dated November 12, 2020.
-
Nov 17, 2020 11:22 AM IST ICICI Direct is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1025 in its research report dated November 12, 2020.
-
Nov 15, 2020 11:56 AM IST Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 980 in its research report dated November 12, 2020.
-
Nov 15, 2020 11:31 AM IST Sharekhan is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1024 in its research report dated November 12, 2020.
-
Nov 13, 2020 10:14 AM IST Key positives for Aurobindo Pharma are sustained performance in the anti-retroviral category and the traction in the US business
-
Nov 12, 2020 01:37 PM IST This will be in addition to its own efforts to develop a vaccine. The company said it is investing Rs 250-Rs 275 crore on a new facility to manufacture vaccines that would be ready by April. The facility will have the capacity to manufacture 400 - 450 million doses of vaccines.
-
Nov 12, 2020 09:48 AM IST Consolidated revenue from operations grew by 15.8 percent year-on-year to Rs 6,483.3 crore with the US formulation business showing a 12.5 percent growth YoY at Rs 3,189.8 crore in Q2.
-
Nov 11, 2020 07:49 PM IST ARV revenue at Rs 502.7 crore increased 111.4 percent YoY and API revenue at Rs 829 crore rose 2.9 percent YoY for the quarter ended September 2020, the company said in its BSE filing.
-
Oct 28, 2020 01:19 PM IST Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 985 in its research report dated October 26, 2020.
-
Oct 27, 2020 02:00 PM IST ICICI Direct is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1025 in its research report dated October 26, 2020.
-
Oct 27, 2020 09:24 AM IST The Natrol sale will help Aurobindo Pharma focus on the core generic drug and injectable businesses
-
Oct 26, 2020 10:34 AM IST Jefferies served as the sole financial adviser and Sullivan & Cromwell LLP acted as legal counsel to Aurobindo.
-
Sep 28, 2020 11:22 PM IST Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1030 in its research report dated September 27, 2020.